Cardiorenal Research Laboratory, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Cardiorenal Research Laboratory, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
JACC Heart Fail. 2021 Sep;9(9):613-623. doi: 10.1016/j.jchf.2021.04.013. Epub 2021 Jul 7.
This study sought to characterize urinary and plasma C-type natriuretic peptide (CNP) in acute decompensated heart failure (ADHF) to define their relationship with clinical variables and to determine whether urinary and plasma CNP together add prognostic value.
CNP is a protective hormone that is synthesized in the kidney and endothelium and possesses antiremodeling properties. Urinary and plasma CNP levels are elevated in pathophysiological conditions; however, their regulation and prognostic value in heart failure (HF) is unclear.
Urinary and plasma CNP were measured in 109 healthy subjects and 208 patients with ADHF; the 95th percentile of CNP values from healthy subjects established the normal contemporary cutoffs. Patients with ADHF were stratified based on urinary and plasma CNP levels for clinical characterization and the assessment of risk for adverse outcomes.
There was no significant correlation between urinary and plasma CNP in both cohorts. Urinary and plasma CNP were significantly elevated in patients with ADHF, and both increased with disease severity and were positively correlated with plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP). Of the patients with ADHF, 23% had elevations in both urinary and plasma CNP, whereas 24% had normal CNP levels. During a median follow-up of 3 years, patients with elevated urinary and plasma CNP had a significantly higher risk of rehospitalization and/or death (HR: 1.79; P = 0.03) and rehospitalization (HR: 2.16; P = 0.01) after adjusting for age, sex, left ventricular ejection fraction, renal function, and plasma NT-proBNP. The C-statistic and integrated discrimination analyses further supported that the addition of urinary and plasma CNP to established risk models improved the prediction of adverse outcomes in patients with ADHF.
Urinary and plasma CNP are differentially regulated in ADHF, and elevations in both provided independent prognostic value for predicting adverse outcomes.
本研究旨在描述急性失代偿性心力衰竭(ADHF)患者的尿和血浆 C 型利钠肽(CNP)特征,明确其与临床变量的关系,并确定尿和血浆 CNP 联合是否具有预后价值。
CNP 是一种在肾脏和内皮细胞中合成的保护性激素,具有抗重构特性。在病理生理条件下,尿和血浆 CNP 水平升高;然而,其在心力衰竭(HF)中的调节和预后价值尚不清楚。
测量了 109 名健康受试者和 208 名 ADHF 患者的尿和血浆 CNP;健康受试者的 CNP 值第 95 百分位建立了正常的当代截止值。根据尿和血浆 CNP 水平对 ADHF 患者进行分层,进行临床特征描述和不良结局风险评估。
在两个队列中,尿和血浆 CNP 之间均无显著相关性。ADHF 患者的尿和血浆 CNP 均显著升高,且随疾病严重程度增加而升高,并与血浆 N 末端 pro-B 型利钠肽(NT-proBNP)呈正相关。在 ADHF 患者中,23%的患者尿和血浆 CNP 均升高,而 24%的患者 CNP 水平正常。在中位随访 3 年期间,尿和血浆 CNP 升高的患者再住院和/或死亡(HR:1.79;P=0.03)和再住院(HR:2.16;P=0.01)的风险显著增加,调整年龄、性别、左心室射血分数、肾功能和血浆 NT-proBNP 后。C 统计量和综合鉴别分析进一步支持,在 ADHF 患者中,尿和血浆 CNP 的联合应用可改善对不良结局的预测。
尿和血浆 CNP 在 ADHF 中差异调节,两者升高均为预测不良结局的独立预后因素。